Hormonal
The metabolic benefits of 2'-fucosyllactose (increased HDL, insulin, FGF21) are contingent on the subject being a 'responder' who experiences a bloom in Bifidobacterium abundance.
Not everyone will benefit from 2'-fucosyllactose. If you don't have Bifidobacterium in your gut, you might not see the metabolic improvements (like better HDL or insulin sensitivity) that others do. Testing your microbiome might help predict if this supplement is right for you.
Bifidobacterium 'responders' experienced additional metabolic and proteomic changes and also performed better on a cognitive test of visual memory. Nonresponders were more likely to lack Bifidobacterium in their gut microbiota at the start of the intervention.
Why this rating
Post-hoc analysis of a randomized controlled trial; while statistically significant, it is a subgroup analysis.
Source
A human milk oligosaccharide alters the microbiome, circulating hormones, and metabolites in a randomized controlled trial of older adults
Matthew M. Carter et al. · Cell Reports Medicine · 2025
DOI 10.1016/j.xcrm.2025.102256
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →